170 related articles for article (PubMed ID: 36499357)
41. Biased antagonism of CXCR4 avoids antagonist tolerance.
Hitchinson B; Eby JM; Gao X; Guite-Vinet F; Ziarek JJ; Abdelkarim H; Lee Y; Okamoto Y; Shikano S; Majetschak M; Heveker N; Volkman BF; Tarasova NI; Gaponenko V
Sci Signal; 2018 Oct; 11(552):. PubMed ID: 30327409
[TBL] [Abstract][Full Text] [Related]
42. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA.
Verhofstede C; Vandekerckhove L; Eygen VV; Demecheleer E; Vandenbroucke I; Winters B; Plum J; Vogelaers D; Stuyver L
J Acquir Immune Defic Syndr; 2009 Feb; 50(2):126-36. PubMed ID: 19131897
[TBL] [Abstract][Full Text] [Related]
43. The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated With Radiation Therapy and Concurrent Chemotherapy.
Chaudary N; Hill RP; Stulik L; Milosevic M
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1317-1324. PubMed ID: 33771702
[TBL] [Abstract][Full Text] [Related]
44. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors.
Toma J; Whitcomb JM; Petropoulos CJ; Huang W
AIDS; 2010 Sep; 24(14):2181-6. PubMed ID: 20639728
[TBL] [Abstract][Full Text] [Related]
45. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.
Chabot DJ; Zhang PF; Quinnan GV; Broder CC
J Virol; 1999 Aug; 73(8):6598-609. PubMed ID: 10400757
[TBL] [Abstract][Full Text] [Related]
46. High-resolution imaging and single-cell analysis via laser ablation-inductively coupled plasma-mass spectrometry for the determination of membranous receptor expression levels in breast cancer cell lines using receptor-specific hybrid tracers.
Van Acker T; Buckle T; Van Malderen SJM; van Willigen DM; van Unen V; van Leeuwen FWB; Vanhaecke F
Anal Chim Acta; 2019 Oct; 1074():43-53. PubMed ID: 31159938
[TBL] [Abstract][Full Text] [Related]
47. The two human CXCR4 isoforms display different HIV receptor activities: consequences for the emergence of X4 strains.
Duquenne C; Psomas C; Gimenez S; Guigues A; Carles MJ; Barbuat C; Lavigne JP; Sotto A; Reynes J; Guglielmi P; Mettling C; François V; Corbeau P
J Immunol; 2014 Oct; 193(8):4188-94. PubMed ID: 25230750
[TBL] [Abstract][Full Text] [Related]
48. A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life.
Lindgren J; Refai E; Zaitsev SV; Abrahmsén L; Berggren PO; Karlström AE
Biopolymers; 2014 May; 102(3):252-9. PubMed ID: 24549714
[TBL] [Abstract][Full Text] [Related]
49. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
Fernàndez G; Llano A; Esgleas M; Clotet B; Esté JA; Martínez MA
J Gen Virol; 2006 May; 87(Pt 5):1285-1294. PubMed ID: 16603531
[TBL] [Abstract][Full Text] [Related]
50. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
Wang J; Babcock GJ; Choe H; Farzan M; Sodroski J; Gabuzda D
Virology; 2004 Jun; 324(1):140-50. PubMed ID: 15183061
[TBL] [Abstract][Full Text] [Related]
51. CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains.
Lin YL; Portales P; Segondy M; Baillat V; de Boever CM; Le Moing V; Réant B; Montes B; Clot J; Reynes J; Corbeau P
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):530-6. PubMed ID: 16044003
[TBL] [Abstract][Full Text] [Related]
52. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.
Bunnik EM; Quakkelaar ED; van Nuenen AC; Boeser-Nunnink B; Schuitemaker H
J Virol; 2007 Jan; 81(2):525-31. PubMed ID: 17079299
[TBL] [Abstract][Full Text] [Related]
53. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
Kratz F
J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
[TBL] [Abstract][Full Text] [Related]
54. Half-life extension using serum albumin-binding DARPin® domains.
Steiner D; Merz FW; Sonderegger I; Gulotti-Georgieva M; Villemagne D; Phillips DJ; Forrer P; Stumpp MT; Zitt C; Binz HK
Protein Eng Des Sel; 2017 Sep; 30(9):583-591. PubMed ID: 29088432
[TBL] [Abstract][Full Text] [Related]
55. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
[TBL] [Abstract][Full Text] [Related]
56. CCR5 N-terminus peptides enhance X4 HIV-1 infection by CXCR4 up-regulation.
Dettin M; Zanchetta M; Pasquato A; Borrello M; Piatier-Tonneau D; Di Bello C; De Rossi A
Biochem Biophys Res Commun; 2003 Aug; 307(3):640-6. PubMed ID: 12893271
[TBL] [Abstract][Full Text] [Related]
57. Antibody enrichment and mass spectrometry of albumin-Cys34 adducts.
Chung MK; Grigoryan H; Iavarone AT; Rappaport SM
Chem Res Toxicol; 2014 Mar; 27(3):400-7. PubMed ID: 24328277
[TBL] [Abstract][Full Text] [Related]
58. Pairwise comparison of isogenic HIV-1 viruses: R5 phenotype replicates more efficiently than X4 phenotype in primary CD4+ T cells expressing physiological levels of CXCR4.
Fiser AL; Lin YL; Portalès P; Mettling C; Clot J; Corbeau P
J Acquir Immune Defic Syndr; 2010 Feb; 53(2):162-6. PubMed ID: 20051874
[TBL] [Abstract][Full Text] [Related]
59. High CD4(+) T-cell surface CXCR4 density as a risk factor for R5 to X4 switch in the course of HIV-1 infection.
Fiser AL; Vincent T; Brieu N; Lin YL; Portalès P; Mettling C; Reynes J; Corbeau P
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):529-35. PubMed ID: 20861743
[TBL] [Abstract][Full Text] [Related]
60. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
Weiser B; Philpott S; Klimkait T; Burger H; Kitchen C; Bürgisser P; Gorgievski M; Perrin L; Piffaretti JC; Ledergerber B;
AIDS; 2008 Feb; 22(4):469-79. PubMed ID: 18301059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
